Primary outcome was in-hospital all-cause mortality. Analysis included logistic regression for the whole-patient sample, conditional logistic regression for PSM sample, and competing risk approach for time-to-event analysis. PSM with an optimal algorithm was performed, matching cases (CP recipients) on baseline patient characteristics to select (178) controls in a 1:1 ratio. Methodology: This propensity score matched (PSM) case–control study included a total of 477 adult patients with COVID-19 (≥18 years of age) with moderate and severe disease out of which 181 patients received CP having neutralizing antibody titers ≥1:40 (PRNT/MNT). This study reports on the effectiveness of CP therapy (CPT) in patients with moderate and severe COVID-19 in an Indian cohort. There still exists uncertainty on the safety and efficacy of CP as a therapeutic option in COVID-19. Source of Support: None, Conflict of Interest: Noneīackground: Convalescent plasma (CP) in coronavirus disease 2019 (COVID-19) acts as a source of neutralizing antibodies that could provide passive immunity. Nishant Ramanĭepartment of Medicine, Base Hospital, Delhi Cantt, Pin Code: 110010 Ashta 3, Anirudh Anilkumar 7ġ Department of Respiratory Medicine, Base Hospital, Delhi Cantt, India 2 Department of Respiratory Medicine, Army College of Medical Sciences, Delhi Cantt, India 3 Department of Medicine, Base Hospital, Delhi Cantt, India 4 Command Hospital, Central Command, Lucknow, Uttar Pradesh, India 5 Department of Gastroenterology, Base Hospital, Delhi Cantt, India 6 Department of Pathology, Base Hospital, Delhi Cantt, India 7 House Surgeon, Sir Ganga Ram Hospital, New Delhi, India Date of SubmissionĬorrespondence Address: Dr. Kislay Kishore 1, Sandeep Rana 1, Vasu Vardhan 2, Nishant Raman 3, Sandeep Thareja 4, K.V. Propensity score-matched case–control study of convalescent plasma in treatment of patients with moderate and severe COVID-19